BD Gets Enterprise Level Cybersecurity Assessment From UL

Becton, Dickinson and CompanyBDX , popularly known as BD, recently announced an enterprise level cybersecurity assessment by the UL Healthcare. This ensures that all medical devices developed by the company will be in line with the UL Cybersecurity Assurance Program ("UL CAP").

The company received UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software. The UL CAP version of the BD FACSLyric flow cytometer will be available in 2019.

What is UL CAP?

UL CAP incorporates the UL 2900 set of standards, including UL 2900-1. This is a software cybersecurity standard for network-connected medical devices that has official recognition from the FDA.

More about BD FACSLyric Flow Cytometer

The BD FACSLyric flow cytometer, used with BD Multitest assays, is intended for immunological assessment of individuals and patients having immune deficiency.

Price Performance

In the past year, BD has outperformed the industry to which it belongs in terms of share price. The company's shares have returned 8.1% compared with the industry's 2.7% decline. However, the current return is marginally lower than the S&P 500's decrease of 0.9%. The stock has a Zacks Rank #3 (Hold).

Product Portfolio Solid

A diverse product portfolio is a key catalyst for BD. Recently, BD announced the launch of BD FACSymphony S6 cell sorter, which was displayed at the 33rd Congress of the International Society for Advancement of Cytometry in Prague. Per management, the new platform enables researchers to sort cell populations to better study cell phenotypes for immunology and multi-omics research.

BD's Alaris Pump and Pyxis ES in the Medical segment, BD MAX, BD FACSLyric continue to boost results. Management is also optimistic about consistent expansion of the BD Horizon Brilliant dyes in Life Sciences and Lutonix AV and Covera in the Interventional segment.

Additionally, BD announced the plan for commercial availability of BD Synapsys microbiology informatics solution, which provides laboratories with secure connectivity across instruments and locations. Additionally, management confirmed that the company is on track to provide sodium chloride saline to customers through a partnership with Fresenius Medical Care.

Management has confirmed that there are newer products in the company's pipe line.

Stocks to Consider

A few better-ranked stocks in the broader medical space are Quidel Corporation QDEL , STAAR Surgical Company STAA and Illumina, Inc ILMN .

Quidel has long-term expected earnings growth rate of 25% and sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

With a Zacks Rank #1, STAAR Surgical delivered average four-quarter positive earnings surprise of 400%.

Illumina's long-term earnings growth rate is projected at 23.4%. The stock carries a Zacks Rank #2 (Buy).

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Quidel Corporation (QDEL): Free Stock Analysis Report

Illumina, Inc. (ILMN): Free Stock Analysis Report

STAAR Surgical Company (STAA): Free Stock Analysis Report

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More